quizartinib Vanflyta
Selected indexed studies
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2023) [PMID:37116523]
- Acute myeloid leukemia management and research in 2025. (CA Cancer J Clin, 2025) [PMID:39656142]
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. (J Hematol Oncol, 2024) [PMID:39538314]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Acute myeloid leukemia management and research in 2025. (2025) pubmed
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) pubmed
- Quizartinib. (2006) pubmed
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. (2024) pubmed
- Quizartinib. (2012) pubmed
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. (2019) pubmed
- Quizartinib (Vanflyta) for acute myeloid leukemia. (2023) pubmed
- Contemporary Management of Acute Myeloid Leukemia: A Review. (2024) pubmed
- PMID:41592166 (2025) pubmed
- Current status and research directions in acute myeloid leukemia. (2024) pubmed